Christina Grek
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$5.9MFederal grants as PI6 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
6 awards · $5.9M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 30, 2022 | NIH | SBIR Phase I Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy | $315K | FIRSTSTRING RESEARCH INC |
| Sep 30, 2022 | NIH | SBIR Phase I Evaluation of a Connexin-based Peptide for the Treatment of Diabetic Retinopathy | $315K | FirstString Research, Inc |
| Jul 1, 2021 | NIH | SBIR Phase II Improving marginal allograft outcomes through cell junction stabilization in transplantation | $2.0M | FIRSTSTRING RESEARCH INC |
| Jul 1, 2021 | NIH | SBIR Phase II Improving marginal allograft outcomes through cell junction stabilization in transplantation | $2.0M | FirstString Research, Inc |
| Sep 15, 2020 | NIH | SBIR Phase I Novel small molecule HSP90 inhibitor for the management of atopic dermatitis | $252K | Regranion, LLC |
| Sep 6, 2018 | NIH | SBIR Phase II Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | $1.6M | FIRSTSTRING RESEARCH INC |
| Sep 6, 2018 | NIH | SBIR Phase II Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide | $1.6M | FirstString Research, Inc |
| Aug 8, 2018 | NIH | SBIR Phase II A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis | $572K | Regranion, LLC |
| Sep 26, 2017 | NIH | SBIR Phase II A Novel Topical HSP90 Inhibitor (CTXT-102) in the Treatment of Mild to Moderate Plaque Psoriasis | $1.2M | Regranion, LLC |
Peer ranks
Federal funding#194
Awards as PI#315
Patents#273
Companies
- FirstString Research, IncLinked by awards · Biotech
- FIRSTSTRING RESEARCH INCLinked by awards
- Regranion, LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.